Codexis expands range of Codex Biocatalyst Panels
US-based biotechnology company Codexis has made four new additions to its portfolio of Codex Biocatalyst Panels. The new panels cover classes of enzymes that can produce a broad range of chemicals widely used by the pharmaceutical industry.
US-based biotechnology company Codexis has made four new additions to its portfolio of Codex Biocatalyst Panels. The new panels cover classes of enzymes that can produce a broad range of chemicals widely used by the pharmaceutical industry.
Earlier this year Codexis introduced the first panel, the Codex KRED Panel for development of new biocatalyst-based manufacturing processes for chiral alcohols. The four new panels are:
- Codex Acylase for chiral amines or alcohols via resolution of amides or esters;
- Codex ERED for ÃŽ± and/or ÃŽ² chiral ketones, esters and nitriles;
- Codex TA for chiral amines; and
- Codex HHDH for chiral halohydrins, cyanohydrins, amino alcohols, epoxides, diols.
The Codex Acylase and Codex ERED panels will be available in the fourth quarter of 2007 and the other two panels in the first quarter of 2008.
"Since their launch in February, customers have used the Codex KRED Panel to move from initial screening to generating the first kilogram quantities of a target material in a matter of weeks - a substantial reduction in development time," said Dr Peter Seufer-Wasserthal, vice-president and general manager, Codexis Pharma Services Group.
"Panel data can be integrated early in the research process, dramatically reducing the time required by pharmaceutical process chemists to generate a cost-effective, efficient biocatalyst for a desired reaction."